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Abbreviations  
HCV   Hepatitis C virus  
 
CHC   Chronic hepatitis C 
 
IDU   Intravenous drug user  
 
FAH XMU  First Affiliated Hospital Xinjiang Medical University 
 
ID   Infectious Department  
 
DAA   Direct acting antivirals  
 
WHO   World Health Organisation  
 
HCC  Hepatocellular Carcinoma  
 
HIV   Human immunodeficiency virus  
 
HBV   Hepatitis B virus  
 
SPSS  Statistical package for the social sciences  
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Abstract  
Degree project, programme in medicine, 2016  
Perception and attitudes on hepatitis C in China 
Fredrik Askeroth, Institution of Biomedicine, Department of Infectious diseases,  
Sahlgrenska academy, University of Gothenburg.  
 
Background  
Hepatitis C (HCV) is the fourth most common infectious disease an d a major public health 
issue, estimated to affect 13-25 million people in China. To improve the situation, it has been 
suggested that overall knowledge and awareness about HCV needs to increase, although little 
is known about perception and attitudes on HCV in China. 
 
Aim 
This study intended to evaluate perception and attitudes on hepatitis C, to deepen the 




A total of 120 questionnaires and 8 interviews were conducted at the Department of Infectious 
Diseases at First Affiliated Hospital, Xinjiang Medical University, Ürümqi, China between 
20160301- 20160415. Questionnaires were distributed to patients and interviews were 
conducted with HCV-patients, nurses and physicians at the study location.  
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Results 
70.3% of the respondents indicated knowledge on that HCV is a blood borne disease, 88.3% 
that it affects the liver, 45.4% that HCV infection can be asymptomatic and 64.4% that the 
infection can lead to cancer. 33,9% felt that people with HCV diagnosis are discriminated. 




Despite many of the respondents were knowledgeable about the true nature of HCV, this 
study found that there are misperceptions regarding transmission routes and course of 
infection. These misperceptions affect a sound awareness about HCV and attitudes towards 
people living with HCV. Apart from maintaining discrimination, impairing quality of life for 
those living with the infection, it may also affect care seeking behaviour keeping people from 
getting tested and discover the disease at an early stage- issues that needs to be addressed in 
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Background  
Hepatitis C (HCV) is a blood borne pathogen, transmitting after exposure of infected blood. 
The most common transmission routes are syringe sharing among intravenous drug users 
(IDU) and medical procedures- where re-use or use of not sufficiently sterilized medical 
equipment transmits the disease (1). Other sources of transmission, however less common, are 
unsafe sex, vertical transmission, tattooing or needle stick injury among health care workers 
(1, 2). In resource high countries, where blood is screened for HCV and medical practice are 
safer, there is a low risk of iatrogenic spread of disease and IDU is the driving force behind 
HCV transmission. However, in resource limited countries it is more common with iatrogenic 
transmission in addition to transmission within the IDU community (1). Meaning that 
recipients of blood, blood products and patients in need of haemodialysis are at high risk of 
acquiring the disease (1, 2).  
 
Once infected, the natural history of HCV infection is complex. It is estimated that about 15% 
of infected experience a symptomatic infection, showing signs of liver disease with fatigue, 
fever, nausea, pain and sometimes, but not always, showing typical signs of liver failure as 
jaundice or clay like stool (3). Many infected individuals remain however asymptomatic, 
showing no signs of disease. This occurs among as many as 85%, meaning that they remain 
unaware about their infection (3, 4). Estimations, and the numbers published by WHO, are 
that 15-45% of the HCV infected spontaneously clear the infection and 55-80% remain 
viremic after 6 months, the limit for chronic hepatitis C (CHC) (3-6). This is important, not 
only might the infected remain unaware about their disease, at risk of infecting others, but 
also that CHC leads to a slow but steady disease progress with 41% developing cirrhosis after 
30 years (7).  
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This can lead to end stage liver failure and in some cases development of hepatocellular 
carcinoma (HCC) (6, 7). The progress of disease and level of liver damage is dependent on 
several factors, which some are able to modify and others not. Male sex, HCV genotype, 
duration and age when infected are examples of non-modifiable risk factors that are 
associated with higher level of disease progression. Other risk factors such as excessive 
drinking, smoking and co-infection with Hepatitis B or HIV are also contributors to disease 
progression, however able to act upon either with lifestyle choices or by health care measures 
(8).  
 
There is no vaccine against HCV, but CHC is treatable and the landscape of treatment is 
currently changing. The old golden standard treatment consists of Pegylated-Interferon and 
Ribavirin. A treatment regime with long treatment time, 6-12 months, and complex due to 
both oral and injected administration. With this old regime cure-rates vary between 50-80% 
depending on HCV-genotype (9). In addition, this treatment has severe side-effects and keeps 
the individual undergoing treatment in an influenza-like state (10, 11). This regime is being 
phased out in many countries, replaced by the new generation of drugs called direct acting 
antiviral (DAA). These drugs treat CHC with higher efficacy, having less side-effects, easier 
administration and shorter time of treatment (11). However, they are much more expensive 
and not available in all countries, even though efforts have been made to increase access to 
these new treatment regimes (12).  
 
Current estimates claim that 184 million people across the globe are anti-HCV positive, a 
world prevalence rate of 2.8% (13). This meaning, they either have a present infection or have 
had the infection in the past, now cleared. In comparison, the estimated corresponding 
numbers in 1990 were 122 million and 2.3%, respectively, indicating an emerging infectious 
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disease of importance (13). The disease burden of HCV is highest in low- or middle-income 
countries and two of the regions with the highest prevalence rates are Central- and East-Asia 
(13). It is estimated that HCV contributes to 27% of all cirrhosis and 25% of all HCC 
worldwide, being the cause of 211.000 cirrhosis associated- and 155.000 HCC associated-
deaths annually (14). In 2014 the World Health organization (WHO) published guidelines for 
policy-makers, government officials and health care workers to be a support on decision 
making in low- and middle-income countries on how to manage treatment and prevention of 
HCV. In these guidelines WHO states that, among other actions, access to screening, reliable 
testing, assessment for risk behaviour and access to treatment are the most important factors 
for successful HCV-management (5). Resource limited countries struggle however to cope 
with HCV. WHO acknowledges this and conclude that treatment associated side-effects, the 
need of advanced testing and costs remain barriers to manage the issue of HCV in these 
countries (5, 15). Experts claim that the overall knowledge and awareness about HCV is low 
throughout the world, ultimately leading to continued transmission of HCV and patients 
remaining unaware of being infected (15-17).  
 
Hepatitis C in China 
HCV is the fourth most common infectious disease and a major public health issue in China 
(18). It is estimated that the current prevalence is 1-1.9%, but these numbers are uncertain  
and there are substantial regional differences in prevalence (19, 20). To put this uncertainty in 
context, the overall prevalence was estimated to 3.2% in 1992 and in 0.4% in 2006, numbers 
however disputed because of the sampling strategies used in these studies (18, 21). But, it is 
believed that China has experienced a true decline in prevalence, a decline attributed to safer 
medical practice, screening of blood products, banishing of paid blood donors and better 
access to testing and treatment for HCV infected (21, 22). Even though this trend is positive- 
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it should be remembered that due to Chinas large population, a prevalence of 1-1.9% means 
that 13-25 million people are anti-HCV positive (22). It should also be noted, regarding 
transmission routes and prevalence, that China is currently facing a situation where medical 
practice has become more safe and IDU has become the driving force behind HCV 
transmission (23). The use of drugs has increased since 1990, and in 2005 there were 1,16 
million registered drug users, a number that in reality could be higher (23). In the group of 
IDUs, it has been reported that the HCV-prevalence could be as high as 61%, and Xinjiang, a 
node for drug trafficking, is considered to be a high-prevalence region (23, 24).  
 
Today, there are still many HCV-infected in China that remain undiagnosed and fail to 
complete treatment, even though efforts have been made (18, 22, 25). This situation is 
although not unique for China. From a world perspective it has been reported that as many as 
50-75% of HCV-infected remain unaware about their infection and when diagnosed they fear 
treatment related side-effects, economical and social hardships as a result of HCV infection 
(26, 27). These are examples of barriers to care, issues that can be improved with education 
and higher knowledge when health care keeps patients and public informed (28, 29). As a 
result of the infection, HCV infected may also encounter discrimination, stigmatisation and 
social vulnerability, both in health care and society (30, 31). This may not only affect 
treatment and care seeking behaviour, but also how HCV infected is viewed upon, affecting 
them on a personal level (28).  
 
The view among Australian women living with HCV is that this situation of discrimination 
and stigmatisation is due to low knowledge about the true nature of HCV among non-infected 
(32). It should be remembered that knowledge is one of the factors that influences attitudes 
and perceptions of a disease (28, 31). Sadly, it has been reported that maybe as low as 1% of 
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the Chinese population have some kind of knowledge about HCV, especially in rural areas 
(21, 22, 33). Further, it has also been reported that Chinese non-hepatitis specialist have little 
knowledge about HCV, a threat for early detection, care and treatment of HCV-patients (34).  
 
The issue of public and health care knowledge about HCV was addressed by Duan et al in a 
review article from 2014. Duan et al states that China should, to lower its HCV disease 
burden, strive to meet earlier diagnosis with screening risk populations, exchange current 
treatment regimes to DAA and raise public and health care awareness about hepatitis C virus 
infection (22). To understand the circumstances and the Chinese prerequisites under which 
these changes are to be made, it should be remembered that the Chinese health care struggles 
with health inequities, trust issues and a failing medical insurance system (35). And, even 
though China reported to WHO in 2013 that development of guidelines and actions to act on 
the issue of HCV was undertaken, it has been indicated that there are differences between 
guidelines and the real-life clinical care of HCV-infected (25, 36).  
 
The field of research regarding perception and attitudes towards hepatitis C in a Chinese 
general population is scarce. Since these factors influence the management of HCV, the 
objective of this study was to investigate and hopefully display a wide extent of perceptions 
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Ürümqi, Xinjiang and study setting 
Ürümqi is situated in the absolute North West of China and is the regional capital of Xinjiang 
Uyghur Autonomous Region. By 2010 it was estimated to have approximately 3 million 
inhabitants (37). Ürümqi is home to Uyghurs, one of Chinas acknowledged minority groups, 
but the majority of the city’s population is Han-Chinese. It is an important economical and 
industrial node of Western China inland. This study was conducted at The First Affiliated 
Hospital of Xinjiang Medical University, which serves a great number of patients being the 
largest hospital in the region. The department of infectious disease had 64635 patient visits 
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Purpose and Aim 
To evaluate perceptions and attitudes regarding hepatitis C among both hepatitis C infected 
and non-infected patients in Ürümqi, China. 
 
Scientific issues 
•   To evaluate perceptions of HCV disease, -transmission and -prevention. 
•   To investigate perceptions on accessibility to testing and treatment of HCV. 
•   To investigate attitudes towards HCV infected, regarding discrimination by either 
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Method  
This explorative study, including a questionnaire based survey and complementary 
interviews, was conducted at Department of Infectious Diseases (ID), First Affiliated Hospital 
(FAH), Xinjiang Medical University (XMU) in Ürümqi, China between 20160301 to 
20160415.  
 
Method considerations  
Before the study was conducted, it was assessed that a mixed methodology was the best way 
of answering the scientific purpose given the prerequisites with short time period for data 
collection and none of the researchers speaking Chinese. Using questionnaires and interviews 
was assessed to generate both quantitative and nuanced data, possibly generating hypotheses 
in this field of research.  
 
After searching the existing literature, looking for similar studies with published or validated 
questionnaires, no questionnaire was found that suited this study. Therefore, a questionnaire 
was developed and designed, aiming to in greatest possible extent answer the scientific 
purpose. The final questionnaire was intended to be kept short, to maximise participation. A 
questionnaire design with a majority of closed end, one answer alternative questions were 
chosen. This design generates comparable data, enables questionnaire interpretation without 
re-translation and makes the questionnaire easy to complete. 
 
The interview must be constructed in a manner that allows the participant to speak freely 
about the subject, still keeping the subject in mind. Therefore, a semi-structured model of 
interviewing was chosen.  
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Participants and study population  
All patients over 18 years of age, reading or speaking Chinese, seeking care or being admitted 
to ID XMU FAH were regarded eligible for the questionnaire part of the study. This group 
consists of both individuals with and without HCV, with their perception and attitudes on 
HCV respectively. From this cohort a convenience sample was taken. Participants were 
chosen as randomly as possible but without formal randomization. Declination was planned to 
be recorded by the persons distributing the questionnaire. The aim was to include 90 HCV-
infected or a total of 120 respondents- consisting of both HCV-infected and non-infected. 
These numbers were estimated, based on previous similar explorative studies to yield 
interesting results and generate stringent hypothesis that could be explored in future studies. 
The calculations were made in collaboration with my supervisor and a statistician.   
 
The interviews were conducted on 2-3 patients, physicians and nurses, to represent a broad 
spectrum of views on HCV. Patients were recruited from the same cohort that was eligible for 
questionnaires, adding the inclusion criteria of participant having HCV and currently being 
admitted to the in-patient ID. All of the physicians and nurses currently working at the ID 
were regarded as eligible for interviews, this being the inclusion criteria. All participants were 
recruited through a physician working in ID and regarded as convenience samples. 
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Questionnaire 
The purpose of this questionnaire was to be an instrument to assess the respondents’ 
perceptions on HCV as a disease, their attitudes on HCV-management and if they believe 
HCV-infected experience discrimination by any means. The questionnaire was developed by 
reviewing previously published questionnaires and British Medical Journals guidelines for 
developing questionnaires and existing literature (38). The final questionnaire consisted of 12 
questions regarding HCV and 5 demographical questions. On questions regarding HCV, the 
optional answer of “don’t know” or “other” was added to minimize bias of participants 
guessing. To let the respondent answer more freely about the subject, a partial open end 
answer on question number 5 was kept. The demographical questions number 14 and 17 were 
also open ended, since this suits the nature of these questions. The complete questionnaire can 
be reviewed in appendix 1.  
 
Regarding validity, the questionnaire was reviewed by two independent statisticians and two 
pilot studies were conducted, on both a Swedish and Chinese population. This resulted in 
small corrections regarding syntax and order of questions. To suit the study setting, the 
questionnaire was also reviewed by Professor Zheng, associated to the ID XMU FAH. This 
review resulted in exclusion of a five grade likert scale on attitude questions and adding of 
question 5 regarding symptoms of HCV-disease and 17 regarding occupation of the 
participant. One question regarding if the respondent have HBV was also added, although 
disappeared in translation. The final questionnaire was translated to Chinese, the official 
language of the hospital, by the Chinese supervisor associated to this study, and re-translated 
to English by a non-professional translator. After distribution it was realised that the Chinese 
characters for hepatitis C are translated to “the third virus liver inflammation”. Even though 
this affects interpretation of the data, the original form was kept, since this issue did not 
appear until a substantial amount of questionnaires had been distributed.   
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Data Collection   
A cover letter was developed to introduce, retrieve informed consent and information on how 
to complete the questionnaire. This letter of introduction was however not used since, in 
China, this information is traditionally given orally by the person handing out the 
questionnaire. All questionnaires were given an individual number and were handed out by a 
physician or a nurse to patients they judged fulfil our inclusion criteria, which took between 1 
and 21 days. The respondents’ answers were not planned to be validated in any way. Patients 
were approached, given a short introduction and then filled out the questionnaires with no 
assistance. If the participant had trouble reading, the questionnaire was completed orally, 
assisted by the person distributing the questionnaire. After the questionnaire was completed, 
the participant handed in the questionnaire to the health care staff who had distributed it. The 
questionnaires were then retrieved, either later that same day or several days later. 
Distribution can be reviewed in table 1.  
 
Table 1: Displaying distribution of questionnaires, which department, date distributed, how 
many that responded and how many questionnaires that were lost. 
Department  Date distributed Distributed Respondents Lost 
Inpatient dpt*  160310-160311 24 17 1 
Inpatient dpt* 160314-160318 32 18 11 
Outpatient dpt* 160322-160412 50 24 1 
Inpatient dpt* 160406-160406 51 34 17 
Inpatient dpt* 160413-160414 27 27 0 
   







* Dpt = department 
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Questionnaire data input 
A questionnaire input sheet was constructed in Software Package of Social Sciences (SPSS) 
and participants’ answers were filled in this sheet. On all questions the absence of an answer 
or unable to understand the respondents answer was marked in SPSS as missing. Regarding 
questions 1-9, aiming to measure the respondents’ perception of HCV, each correct answer 
was given one point and failing to do so, or leaving the question unanswered, gave zero 
points. If an answer consisted of conflicting data, for instance given 2 or more answers, it was 
regarded as don’t know. On questions 1-9 the total score of correct answers was calculated 
manually and then added to SPSS, maximum score being 15. Since this study did not aim to 
evaluate if the respondents has sufficient knowledge about HCV or not, a total score that 
correlates to this was not decided. On question 5 and 17, were participants stated symptoms 
and occupation in Chinese, translation to English was conducted at with the assistance of a 
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Interviews 
The purpose of the interviews was to nuance and deepen the understanding of the perceptions 
and attitudes about HCV. After primary analysis of the questionnaire generated data, three 
main topics for the interview were decided and both open and focused questions were 
generated. Two interview sheets were developed, addressing health care professionals and 
patients respectively. The questions were kept simple and understandable since none of the 
participants were native English speakers. The questions can be viewed in appendix 2.  
 
The interviews were conducted in a closed room or aside in the ID, using a voice memo for 
recording. Fredrik Askeroth and Jonas Eriksson conducted the interviews. The interviews 
were conducted in English and if the participant needed translation, the interview was 
interpreted by a non-professional English-speaking colleague associated with the hospital. 
Some of the patients asked to have their relative also attending the interview, this was 
accepted, although the relative was encouraged to not influence the participant. The time for 
interview was between 20-45 minutes. The interviews were transcribed to written English. 
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Data analysis  
Questionnaire-based data were analysed and presented using descriptive statistics. Mann-
Whitney U-test was used to analyse means between the groups and Chi-squared test to 
analyse possible differences in frequencies between the groups. To compare groups, a 
composite knowledge score was manually calculated and added to SPSS. This way of 
comparing groups has been used in prior studies (28).  Data was analysed using the software 
SPSS, statistical package for the social sciences. 
The transcript generated from interviews was interpreted by analysing the answers, trying to 
keep it to as few words as possible, without losing the participants view on the matter. 
Interview generated data were then processed by reading the transcript and important aspects 
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Ethical considerations  
No formal official ethical approval was judged to be needed by the Chinese supervisor since 
the research did not involve any data or methods requiring such. Although it was no formal 
ethical approval, the study was approved by the Xinjiang Medical University.  
 
Questionnaires and interviews were anonymous and participation was voluntary. Participants 
were able to not complete the questionnaire or interview, leaving at any point without stating 
why. This information was given before the questionnaire or interview were conducted and 
was regarded as informed consent. No informed consent form was signed. All data was 
handled confidential and is anonymous.  
 
The research in this study did not involve any of the methods or data that require an ethical 
approval according to Swedish legislation, although a Swedish ethics committee does not 
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Results 
Questionnaire study population 
 In total, 120 patients agreed to participate in the questionnaire part of the study. The study 
sample was equally distributed regarding gender, but there was an overweight of participants 
between 18-29 (31.9%), college educated (57.1%) and not having HCV (80.5%). Among 
HCV infected, there were 13 males and 8 females, mean age was 40 and 56.5% had college 
education. Demographics are shown in table 2.  











Total N Mean age SD* Median age Missing Total N%** 
Gender 
Male 64 41 15 40 4 54.7% 
Female 53 39 13 39 1 45.3% 
Level of education 
None 0 . . . 0 0.0% 
Elementary school 11 54 16 60 1 9.2% 
High school 40 44 14 46 3 33.6% 
College 68 36 12 32 2 57.1% 
HCV Diagnosis 
Yes 23 40 15 41 3 19.5% 
No 95 40 14 40 2 80.5% 
Don't know 0 . . . 0 0.0% 
Table 2: Demographic presentation of questionnaire participants, displaying each group by 
quantity, age and percental distribution within the group (N=120) 
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Results introduction   
The results are presented by each scientific issue with the most important findings displayed 
using charts. In total, frequency of correct answer differed between 88.3% and 45.4%. Mean 
percentage of correct answers regarding disease was 70.7% (median 70.1%), transmission 
routes 66.4% (median 70.3%) and prevention 66.7% (median 66.7%) (a summary of correct 
answers is presented in table 3). Number of participants who choose to not answer the 
question (missing) differed between 0 and 23 and questions regarding transmission routes 
(missing mean 11.2, median 13) and symptoms of HCV disease (missing mean 20.s 3, median 
23) were associated with most missing values. All questionnaire related data is presented in 




Table 3: displaying questions, correct answer option, number and percentages of 
respondents marking the correct answer. The table is coded with colour according to 
which scientific issue the question it belongs (legend in bottom of table) 
Question Correct option Count  % of correct responses
Hepatitis C is a Virus 94 78.3%
Hepatitis C transmits via Blood 83 70.3%
Hepatitis C primarily affects Liver 106 88.3%
A person with hepatitis C can share a towel Yes 51 47.7%
A person with hepatitis C can share a razor No 80 71.4%
A person with hepatitis C can share a syringe No 80 70.2%
A person with hepatitis C can share a shower Yes 74 71.2%
A person with hepatitis C can share a meal Yes 72 67.3%
A person infected with hepatitis C can get yellow skin and eyes Yes 68 70.1%
A person infected with hepatitis C does not always have symptoms Yes 44 45.4%
A person infected with hepatitis C can experience fatigue Yes 83 79.0%
Hepatitis C is diagnosed with a specific blood test Yes 92 76.7%
Hepatitis C can cause cancer Yes 76 64.4%
A person can die of hepatitis C Yes 83 69.7%
Hepatitis C is treatable Yes 68 56.7%
Association with scientific issue is marked by following color: 
Questions regarding perception of HCV as a disease
Questions regarding perception of HCV transmission routes
Questions regarding perception of HCV prevention
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Comparison of total correct answers  
An overall mean score (MS) of correct answers was calculated and used to compare groups. 
From a maximum of 15, overall MS was 9.6 (SD 3.3). Females (MS 10.3) were significantly 
better compared to males (MS 9.1, p<0.05) although there was no difference between 
respondents having HCV (MS 9.7) and not having HCV (MS 9.6 p>0.05). Persons aged 18-
29 (MS 11.4) scored significantly better compared to those aged 40-49 (MS 8.6, p<0.001), 
50-59 (MS 8.8, p<0.05) and older than 60 (MS 7.2, p<0.001) but no significant difference was 
seen compared to those aged 30-39 (MS 10.7, p>0.05). College educated (MS 10.5) were 
significantly better than those with elementary school education (MS 6.2, p<0.001) and high 
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Perceptions of HCV as a disease  
Among all the participants, a knowledge that hepatitis C is a virus and that it affects the liver 
was indicated by 78.3% and 88.3% of respondents, respectively. That jaundice and fatigue are 
symptoms of HCV disease was recognised by 70.1% and 79.0% respectively. Regarding that 
HCV infection can be asymptomatic was correctly indicated by 45.4% of the respondents, 
being the lowest correct percentage of the questionnaire and associated with many of the 
respondents being uncertain of the answer as 21.6% answered don’t know and 33.0% 
answered no (presented in figure 1). Concerning disease outcomes, 64.4% correctly marked 
that HCV-infection can lead to cancer and 69.7% of the respondents indicated knowledge that 
HCV-infection can be fatal. When comparing groups, females knew that infection can be 
asymptomatic to a significantly (p<0.05) greater extent then males and respondents with HCV 
knew that the infection can lead to cancer in significantly (p<0.05) greater extent than those 
not having HCV. No other significant difference was found (p>0.05) between males and 
females or between respondents having HCV compared to those not having HCV.  
 
 
Figure 1: Percentages of how many of all respondents that considered infection with hepatitis 
C can be asymptomatic with the optional answers “yes” (Blue), “no” (orange) and “don’t 
know” (green). Total amount of respondents: 97, missing 23.  
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Perceptions of HCV transmission routes 
Among all of the respondents, 70.3% indicated correct knowledge about that HCV transmits 
via blood. A majority, 71.4%, indicated that HCV infected should not share a razor and 70.2% 
that HCV-infected should not share a syringe. 71.2% indicated that HCV infected can share a 
shower, 67.3% that they can share a meal and 47.7% stated correctly that HCV infected can 
share a towel. No significant difference was found (p>0.05) between males and females or 
between respondents having HCV compared to those not having HCV. Among respondents 
having HCV 42.9% indicated that people with HCV should not share towel, 14.3% that 
people with HCV should not share shower and 28.6% that people with HCV should not share 






Figure 2: Distribution of answers among respondents with hepatitis C, regarding if a person 
with hepatitis C can share towel (purple), shower (green) or meal (orange). Total amount of 
respondents: 14, missing 9 (on all questions) 
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Perceptions of HCV prevention 
Among the respondents, 76.7% indicated knowledge about that HCV is diagnosed with a 
specific blood test and 56.7% stated correctly that HCV infection is treatable. No significant 
difference was found (p>0.05) between males and females or between respondents having 
HCV compared to those not having HCV.  
 
Attitudes on HCV management 
A majority of all the respondents, 79.8%, considered that people who wants to test for HCV 
can do so and 76.5% believed that HCV-infected receives the correct treatment. Among 
respondents with HCV, the majority (82.6%) felt that people who wants to test for HCV can 
do so but, there was a significant amount (p<0.05) that stated no (17.4%) compared to the 
group of persons not having HCV where 78,9% stated yes, 4.2% no and 16.8% don’t know 
(presented in figure 3). There was no significant (p>0.05) difference between the males and 
females.   
Figure:  1 Distribution of answers regarding if a person who wants to test for hepatitis C can do 
so, comparing answers between respondents with and without hepatitis C. Total amount of 
respondents with HCV: 23, missing 0. Total amount of respondents not having HCV 96, missing 1. 
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Attitudes on discrimination of HCV-infected 
HCV-infected were believed to experience discrimination from health care by 10,1% of the 
respondents and the corresponding number for societal discrimination was 33.9% (displayed 
in figure 4). There was a significantly higher proportion of those with HCV (p<0.05) that 
considered that HCV-infected are discriminated by health care, but no significant difference 
was found either between males and females or between people with or without HCV 



















Figure:  2 Distribution of answers regarding if respondents considered that people with hepatitis 
C experience discrimination in either health care (blue) or society (green). Total amount of 
respondents: 119, missing 1 (both questions).  
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Interviews  
The interview part of the study was conducted on 8 persons consisting of 3 physicians, 2 
nurses and 3 patients. The physicians were 35, 40 and 58 years of age and had been working 
as physician for 10, 16 and 35 years respectively. The nurses were 33 and 43, working as 
nurse for 13 and 19 years respectively. One of the patients was 45 and the other two were 66, 
diagnosed with HCV for 2, 13 and 14 years respectively. 
 
Perceptions on hepatitis C 
Seven of the eight interviewed (87.5%) expressed in some way that there are issues regarding 
perceptions of HCV, associated either with low knowledge, among health care professionals 
or in the general population, or the perception that HCV infection is not a severe disease.  
 
“Most people think it is like having a cold, my friend told me that it is a minor 
disease and that I should not care about it.” 
 Patient, 45  
 
“People do not know about HCV, even physicians not working with infectious 
diseases do not pay attention to HCV … Some people believe it transmits by 
speaking and body contact.” 
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HCV management  
All of the interviewed nurses and physicians stated in some way that there are issues 
regarding HCV management. They considered that knowledge and awareness needs to be 
improved in both health care, among those not working with hepatitis C, and the general 
population.  
 “There are a lot of patients who don’t know that they have HCV” 
 Physician, 58 
 
“Physicians working in other departments know too little about HCV, there is a 
need to improve the management of HCV on all levels”  
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Discrimination of HCV-infected  
Seven of eight interviewed (87.5%) expressed that people with HCV diagnosis experience 
discrimination in various extent. The exception being one interviewed patient who expressed 
that having HCV does not affect the daily life and had no experience of discrimination. One 
interviewed physician estimated that 30% of the HCV infected experience discrimination. The 
interviewed mentioned issues regarding that it is hard for people with HCV-diagnosis to be 
open about it and that other people are afraid to touch or meet them.  
 
“People think that HCV infected should be kept away, only a few think it is ok. 
People who have HIV, can maybe tell, but not as many with HCV. People with 
HCV only tell persons close to them, so they can have a normal life.”  
-   Nurse, 43 
 
“Me, working as a physician, experience discrimination, people are afraid of 
me, working at the infectious department. It is really hard to change.” 
-   Physician, 35  
 
“In China, because 20 years ago, China was a developing country and a poor 
country. So especially in Xinjiang there were often outbreaks of infectious 
diseases. Now China is richer than 20 years ago but the feeling is that, the 
mentality has not changed regarding infectious diseases. I think this is some of 
the discrimination. But now it is changing, but I think it is changing very slowly. 
Since the recent development of treatment, I hope that people stop fearing 
HCV.” 
-   Physician, 58 
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“I don’t think anyone with HCV tell other people about it … My old friends do 
not meet me as often anymore, they do not want to eat with me, they’re afraid of 
the HCV that I have.”  
-   Patient, 66  
 
“A lot of people hate people with HCV. I am depressed and feel so much pain, 
both physical and mental. People say “you have HCV, I do not want to be near 
you”, although I think that it is a minority who thinks like this. People who have 
no knowledge discriminate people with HCV.”  
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Discussion  
The findings in this study suggest that the majority, about two thirds, of the respondents had a 
correct perception of the core characteristics about HCV, knowing it is a viral, blood borne 
disease that affects the liver and that can be detected by a specific blood test. The overall 
findings of 50-90% correct answer rate are in line with previous studies (27, 28, 33). Level of 
education, being female and between 18-29 years of age were associated with a higher 
indicated composite knowledge, differing from a previous partly Chinese study were only 
length of education were associated with a higher test score (33). This study found no 
difference in composite knowledge between responders having HCV compared to those who 
have not. Regardless was this stand for, it could be argued that a person having a disease 
should be more educated compared to those who have not, especially since patient education 
have been shown to improve treatment rates and patient attitude towards treatment (29). It is 
hard to determine whether or not this is representative for a bigger population, but underlines 
the need for further research to decrease transmission of disease.   
  
Despite that many of the respondents displayed knowledge on transmission routes, 20-25% of 
the respondents indicated that there is no harm in sharing razor or needle with a person who 
has HCV infection, putting them at risk for acquiring the infection. In addition, several of the 
HCV-infected did not indicate knowledge of the true transmission routes of infection, putting 
them in situations where they might experience internal shame or insecurity, which have been 
shown in prior studies (30). A limited knowledge on transmission routes among the infected 
and in the general population could contribute to discrimination of HCV infected (32). This 
discrimination is further exampled by the views expressed during interviews were physicians 
and patients stated that people believing it can be transmitted by skin contact or by sharing 
meal and thus leading to avoidance of normal social contact (30, 32).  
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The questionnaire data in this study indicate that, one third of the respondents (33.9%) felt 
that HCV infected experience discrimination. The impact of discrimination on quality on 
daily life for people living with HCV was further stressed by the interview participants, 
confirming findings in prior studies (30, 31). The discrimination of HCV infected has in 
previous studies been shown to range from social situations, work relations and even health 
care, hence affecting the infected on a several levels (30-32, 39). 
 
Discrimination of HCV infected could also negatively affect care seeking behaviour, both 
among people with HCV and those suspecting that they have HCV, hence avoiding being 
tested (31, 39). Although the majority of the responders (79.8%) in this study indicated that 
access to testing is sufficient, there was a significant amount of persons having HCV (17.4%) 
indicating that not everyone can test for HCV, wishing to do so. What this stands for is hard 
to discuss, but studies have reported that HCV infected experience stigmatisation when 
seeking care (31, 32). 
 
Hepatitis C infection is commonly asymptomatic with only half of the infected being aware of 
having HCV (27). The data in this study suggests that 45.4% of the responders had 
knowledge on that HCV-infection can be asymptomatic, being the lowest percentage of 
correct answers in this study. Since the asymptomatic nature of HCV keeps many unaware 
about their infection, an issue that have been called the greatest barrier for treatment of 
hepatitis C (by McGowan et al in 2012), it could be argued that this question should have the 
highest percentage of correct answers (26). This being a bold statement, but a successful 
management of hepatitis C is founded on access to testing and treatment (5, 15, 40). 
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Ideas for future studies  
The findings in this study suggest that future studies are needed, to both deepen and broaden 
the understanding of the subject. A broad, more controlled survey matching participants both 
having and not having HCV could possibly demonstrate correlations with knowledge and 
attitudes towards people having HCV, displaying the findings in this study but more nuanced. 
A study with this design could possibly test the hypothesis that knowledge of, for example, 
transmission routes is a factor influencing discrimination. To fully succeed with such study, a 
complementary qualitative study trying to address the when, why and how persons with HCV 
experience discrimination in a Chinese society, would be of benefit as it would generate more 
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Limitations  
We experienced translational and language barriers throughout the whole study. Since we are 
not speaking Chinese, we did not have the possibility to always communicate instructions 
regarding sample, distribution and completion of questionnaires and interviews, why some 
issues regarding reliability occur. We did also realise that Hepatitis C translates to “the third 
liver inflammation” in Chinese characters, which gives away the answer on question 1 and 3, 
possibly affecting the rate of correct responses. Possible participants, who are illiterate, do not 
read Chinese and because of study location do not visit the hospital, were further excluded 
from participation, which might have affected the results. Although the aim was higher, not 
many participants having HCV were included, and the sample size needs to be regarded when 
interpreting the results. By constructing our own questionnaire, the possibility to extrapolate 
and interpret our result, putting it in a broader context, is limited. Also, the scientific issue 
regarding attitudes to access to treatment were not evaluated as the question “people with 
HCV gets correct treatment” was considered not answering the question hence no conclusions 
was drawn. In conclusion, the findings must be regarded as uncertain and interpreted with 
care. But, the overall findings about HCV perception are in line with previous studies and 
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Conclusion 
There is a need of improving knowledge and awareness about HCV in China (22). The 
findings in this study suggest that about two-thirds of the respondents have a correct 
perception HCV disease and transmission routes. But, unfortunately the study found a 
relatively low indicated knowledge about that HCV-infection can be asymptomatic and many 
respondents considered HCV infected as discriminated. These are issues of importance for 
China to manage and further research is needed to in a more controlled manner assess 
perceptions of HCV and fully understand the how, when and why people with HCV are 
discriminated in the Chinese society. This could present a broader base for intervention, 
possibly improving knowledge through patient and public education, hence improving the 
living conditions for people with hepatitis C and attitudes towards testing and treatment, 
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Populärvetenskaplig sammanfattning på svenska  
Uppskattningsvis är 184 miljoner människor i världen (2.8%) smittade med hepatit C virus 
och i Kina är motsvarande uppskattning 13-25 miljoner (1-1.9%). Hepatit C är ett virus som 
infekterar och bidrar till inflammation i levern. Viruset är blodburet, vilket betyder att den 
överförs efter exponering av infekterat blod. Överföring sker oftast efter att människor som 
injicerar droger delar sprutor eller på grund av osäkra metoder inom sjukvården, vilket är 
associerat till sjukvård i resurssvaga länder där tillgången till säkra metoder kan vara 
begränsad.  
 
Inflammationen leder till ärrbildning, nedsatt funktion av och kan också leda till cancer i 
levern. Hepatit C uppskattas ligga bakom en fjärdedel av världens dödsfall på grund av cirros 
(skrumplever) och levercellscancer. Utvecklingen av skadorna på levern tar ofta lång tid och 
få upplever symtom, vilket leder till att många infekterade inte söker vård.  
 
Kunskap och medvetenheten om hepatit C är en central fråga för smittades tillgång till 
behandling och för minskad smittspridning. För att kunna förbättra kunskapen om hepatit C  
och påverka inställningen till smittade är de viktigt att utforska vilka uppfattningar och 
attityder som finns om  hepatit C. Vår studie syftade till att utröna detta genom att använda 
enkäter patienter samt genomföra intervjuer med både patienter, sjuksköterskor och läkare, 
samtliga på en infektions avdelning i Ürümqi, Kina. Totalt delades 120 enkäter ut och 8 
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Drygt två tredjedelar av studiedeltagarna uppgav att de visste att hepatit C är en blodburen 
smitta som drabbar levern och kan leda till cancer. Knappt hälften svarade att de visste om att 
smittade kan vara fria från symtom. Ungefär en tredjedel ansåg att de med hepatit C blir 
diskriminerade i samhället, något som också uttrycktes under intervjuerna, där de intervjuade 
patienterna bland annat gav exempel på att före detta vänner tagit avstånd på grund av att de 
har sjukdomen. Under intervjuerna berättade även en läkare att det finns de som tror att 
hepatit C kan överföras genom kroppskontakt, vilket är fel.  
 
Fynden i studien talar för att flertalet studiedeltagare hade kunskap om hur hepatit C viruset 
smittar, vilka risker för komplikationer som finns och att det finns behandling. Dock    
förekom det missuppfattningar om att infektion kan smitta via mat och genom att dela dusch 
med smittad samt att smittade kan vara fria från symtom. Detta kan påverka människors 
risktagande, hur de uppfattar sjukdomen samt hur de söker vård. Det kan också bidra till den 
diskriminering som studien fann. Diskrimineringen påverkar inte bara livskvalitén för de som 
har infektionen utan kan även påverka i vilken utsträckning de med hepatit C eller 
odiagnostiserade söker vård och är därmed ett hinder för Kina att förbättra sin hantering av 
hepatit C. Fynden i studien talar för att det finns ett behov att dels förbättra informationen 
som ges angående hepatit C, men också att det finns ett behov av att genomföra fler studier 
om den diskriminering som de med hepatit C utsätts för- då detta är en central faktor i hur 
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Towel( Yes No Don't(know
Razor Yes No Don't(know
Syringe Yes No Don't(know
Shower( Yes No Don't(know





Yellow(skin(and(yellow(eyes Yes No Don't(know
Often(there(are(no(symptoms Yes No Don't(know
Fatigue(( Yes No Don't(know
Other(symtoms,(please(write:
The(questionnaire(continues(on(page(2(
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Appendix 2 – Interview sheet  
Interview sheet for doctor and nurses  
 
 
1.   What do you think is the general populations view on Hepatitis C? 
a.   If you have experienced, please describe any kind of misperceptions about 
hepatitis C that you have met during your clinical work? 
b.   Do you believe this affects HCV management? Why? 
c.   Do you agree to following statement: general populations perceptions (view) 
of hepatitis C affects HCV management? 
 
2.   From your perspective, please describe the HCV-infecteds’ situation in the society? 
a.   Can HCV-infected tell other person they have HCV 
b.   How do you believe this affects the HCV situation? How? 
c.   Do you agree with following statement: HCV-infected experience 
discrimination?  
 
3.   If you could change anything regarding HCV in china, what would you change? Why?  
a.   Do you agree with the following statement: there is a need to act on HCV in 
China? 
 
4.   Regarding this, are there anything else that you would like to add? 
 





Duration working  
 
 
Follow ups:  
Please give examples  
What is the biggest challenge with?  
What are your thoughts on?  
Do you see any other explanations? 
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Interview sheet for patients  
 
 
1.   What is your view on hepatitis C? 
a.   What do you believe is the general populations view on hepatitis C?  
b.   Do you agree with the following statement: most people have an in-correct 
view on hepatitis C?  
 
2.   How would you describe living with hepatitis C? 
a.   How does having HCV affect your daily life? Examples?  
b.   How would you describe your relationship to healthcare? 
c.   If a person has HCV, do you think they can tell other people about it? 
a.   Do you agree with the following statement: HCV-infected experience 
discrimination?  
b.   Have you experienced discrimination  
 
3.   What are your thoughts regarding your future, since you have hepatitis C?  
a.   If you could change anything regarding HCV in china, what would you 
change? Why? 
b.   Do you agree with the following statement: there is a need to act on HCV in 
China? 
 






Duration with HCV     
 
Follow ups:  
Please give examples  
What is the biggest challenge with?  
What are your thoughts on?  
Do you see any other explanations? 
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 Count Column Valid N % Missing 
Gender Male 64 54.7%  
Female 53 45.3%  
Total 117  3 
Age by category 18 - 29  36 31.9%  
30 - 39  20 17.7%  
40 - 49 26 23.0%  
50 - 59  17 15.0%  
60 or older 14 12.4%  
Total 113  7 
Hepatitis C diagnosis Yes 23 19.5%  
No 95 80.5%  
Don't know 0 0.0%  
Total 118  2 
Level of education None 0 0.0%  
Elementary 
school 
11 9.2%  
High school 40 33.6%  
College 68 57.1%  
Total 119  1 
Department In-patient 
department 
96 80.0%  
Out-patient 
department 
24 20.0%  





N Mean Median Std. Deviation Minimum Maximum 
113 39.90 40.00 13.969 18 76 
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Perceptions about HCV as a disease  
 
 Count Column Valid N % Missing 
Hepatitis C is a Bacteria 7 5.8%  
Virus 94 78.3%  
Other 4 3.3%  
Don't know 15 12.5%  
Total 120  0 
Hepatitis C primarily 
affects 
Kidneys 0 0.0%  
Liver 106 88.3%  
Lung 0 0.0%  
Heart 0 0.0%  
Other 0 0.0%  
Don't know 14 11.7%  
Total 120  0 
A person infected with 
hepatitis C can get 
yellow skin and eyes 
Yes 68 70.1%  
No 11 11.3%  
Don't know 18 18.6%  
Total 97  23 
A person infected with 
hepatitis C does not 
always have symptoms 
Yes 44 45.4%  
No 32 33.0%  
Don't know 21 21.6%  
Total 97  23 
A person infected with 
hepatitis C can 
experience fatigue 
Yes 83 79.0%  
No 7 6.7%  
Don't know 15 14.3%  
Total 105  15 
Hepatitis C can cause 
cancer 
Yes 76 64.4%  
No 18 15.3%  
Don't know 24 20.3%  
Total 118  2 
A person can die of 
hepatitis C 
Yes 83 69.7%  
No 16 13.4%  
Don't know 20 16.8%  
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Perceptions about HCV transmission routes 
 
 Count Column N % Missing 
Hepatitis C 
transmits via 
Skin 0 0.0%  
Mucus 2 1.7%  
Blood 83 70.3%  
Air 2 1.7%  
Other 0 0.0%  
Don't know 31 26.3%  
Total 118  2 
A person with 
hepatitis C can 
share a towel 
Yes 51 47.7%  
No 48 44.9%  
Don't know 8 7.5%  
Total 107  13 
A person with 
hepatitis C can 
share a razor 
Yes 23 20.5%  
No 80 71.4%  
Don't know 9 8.0%  
Total 112  8 
A person with 
hepatitis C can 
share a syringe 
Yes 27 23.7%  
No 80 70.2%  
Don't know 7 6.1%  
Total 114  6 
A person with 
hepatitis C can 
share a shower 
Yes 74 71.2%  
No 18 17.3%  
Don't know 12 11.5%  
Total 104  16 
A person with 
hepatitis C can 
share a meal 
Yes 72 67.3%  
No 27 25.2%  
Don't know 8 7.5%  
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Perception about HCV prevention  
 
 Count Column Valid N % Missing 




Yes 92 76.7%  
No 5 4.2%  
Don't know 23 19.2%  
Total 120  0 
Hepatitis C is 
treatable 
Yes 68 56.7%  
No 30 25.0%  
Don't know 22 18.3%  
Total 120  0 
 
!
Attitudes on HCV management 
!
 
 Count Column Valid N % Missing 
If a person 
wants to test 
for hepatitis C, 
they can do so 
Yes 95 79.8%  
No 8 6.7%  
Don't know 16 13.4%  
Total 119  1 
A person 
diagnosed with 
hepatitis C gets 
the correct 
treatment 
Yes 91 76.5%  
No 8 6.7%  
Don't know 20 16.8%  























Attitudes on discrimination of HCV infected  
!
 
 Count Column Valid N % Missing 
People with hepatitis C are 
discriminated by health care 
Yes 12 10.1%  
No 88 73.9%  
Don't know 19 16.0%  
Total 119  1 
People with hepatitis C are 
discriminated in society 
Yes 40 33.9%  
No 55 46.6%  
Don't know 23 19.5%  
Total 118  2 
 
 
 
 
 
!
